Rev. Soc. Esp. Dolor. 2021; 28(13): 80-84 / DOI: 10.20986/resed.2021.3858/2020
Carlos Tornero, Luis Enrique Fernández
ABSTRACT
Osteoarthritis is a degenerative disorder that progresses slowly and is becoming more and more common in our population. Until a few years ago, it has been treated with oral analgesics, intra-articular injections with corticosteroids, botulinum toxin and hyaluronic acid and even with surgical joint replacement in the most advanced cases.
Regenerative medicine is the great hope in the treatment of this pathology to improve the quality of life of patients and try to slow down its progression. There are two types of regenerative intra-articular injection therapies that we must differentiate, PRP (Platelet-rich plasma) and MSC (Mesenchymal stem cells) with promising results.
Although there is the potential benefit of biological therapies acting directly on the affected joint, rigorous and well-designed clinical trials are necessary to establish the safety and efficacy of these therapies.
RESUMEN
La osteoartritis es un trastorno degenerativo que progresa lentamente y cada vez es más frecuente en nuestra población. Hasta hace escasos años se ha tratado con analgésicos orales, inyecciones intrarticulares con corticoides, toxina botulínica y ácido hialurónico e incluso con recambio articular quirúrgico en los casos más avanzados.
La medicina regenerativa es la gran esperanza en el tratamiento de esta patología para mejorar la calidad de vida de los pacientes y tratar de enlentecer su progresión. Existen dos tipos de terapias regenerativas de inyección intrarticular que debemos de diferenciar: el plasma rico en plaquetas (PRP) y las células madre (MSC), con prometedores resultados.
Aunque existe el beneficio potencial de las terapias biológicas actuando directamente en la articulación afectada, son necesarios ensayos clínicos rigurosos y bien diseñados para establecer la seguridad y eficacia de estas terapias.
Nuevo comentario
Comentarios
No comments in this article
Bibliografía
1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. J Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. Rheumatol. 1988;15(12):1833-40.
2. Wernecke C, Braun HJ, Dragoo JL. The effect of intra-articular corticosteroids on articular cartilage: a systematic review. Orthop J Sports Med. 2015;3(5):2325967115581163. DOI: 10.1177/2325967115581163.
3. Buendía-López D, Medina-Quirós M, Fernández-Villacañas Marín MA. Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a randomized controlled trial. J Orthop Traumatol. 2018;19(1):3. DOI: 10.1186/s10195-018-0501-3.
4. Sucuoğlu H, Üstünsoy S. The short-term effect of PRP on chronic pain in knee osteoarthritis . AGRI. 2019;31(2):63-9. DOI: 10.14744/agri.2019.81489.
5. Filardo G, Kon E, Di Martino A, Di Matteo B, Merli ML, Cenacchi A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 2012;13:229. DOI: 10.1186/1471-2474-13-229.
6. Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504-11. D·OI: 10.1002/sctm.18-0122.
7. Marx RE. Platelet-rich plasma: Evidence to support its use. J Oral Maxil Surg. 2004;62(4):489-96. DOI: 10.1016/j.joms.2003.12.003.
8. Griffin XL, Smith CM, Costa ML. The clinical use of platelet-rich plasma in the promotion of bone healing: A systematic review. Injury. 2009;40(2):158-62. DOI: 10.1016/j.injury.2008.06.025.
9. Schmidt MB, Chen EH, Lynch SE. A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair. Osteoarthr cartilage. 2006;14(5):403-12. DOI: 10.1016/j.joca.2005.10.011.
10. Guillibert C, Charpin C, Raffray M, Benmenni A, Dehaut FX, Ghobeira GE, et al. Single injection of high volume of autologous pure PRP provides a significant improvement in knee osteoarthritis: a prospective routine care study. Int J Mol Sci. 2019;20(6):1327. DOI: 10.3390/ijms20061327.
11. Kon E, Engebretsen L, Verdonk P, Nehrer S, Filardo G. Autologous Protein Solution Injections for the Treatment of Knee Osteoarthritis: 3-Year Results. Am J Sports Med. 2020;48(11):2703-10. DOI: 10.1177/0363546520944891.
12. National Institute for Health and Clinical Excellence (NICE). NICE Interventional Procedures Guidance 637. Platelet-rich plasma injections for knee osteoarthritis. [Internet]. January 2019. Disponible en: http://www.nice.org.uk/guidance/ipg637.
13. The Royal Australian College of General Practitioners. Guideline for the management of knee and hip osteoarthritis [Internet]. 2nd ed. East Melbourne, Vic: RACGP; 2018 [consultado el 15 de noviembre de 2020]. Disponible en: https://www.racgp.org.au/download/Documents/Guidelines/Musculoskeletal/guideline-for-the-management-of-knee-and-hip-oa-2nd-edition.pdf.
14. Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Núñez-Córdoba JM, López-Elío S, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II). J Transl Med. 2018;16(1):213. DOI: 10.1186/s12967-018-1591-7.
15. Al-Najar M, Khalil H, Al-Ajlouni J, Al-Antary E, Hamdan M, Rahmeh R, et al. Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study. J Orthop Surg Res. 2017;12(1):190. DOI: 10.1186/s13018-017-0689-6.
16. Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254-66. DOI: 10.1002/stem.1634.
17. Chahal J, Gómez-Aristizábal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio A, et al. Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation. Stem Cells Transl Med. 2019;8(8):746-57. DOI: 10.1002/sctm.18-0183.
18. Freitag J, Bates D, Wickham J, Shah K, Huguenin L, Tenen A, et al. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen Med. 2019;14(3):213-30. DOI: 10.2217/rme-2018-0161.
19. Delgado-Enciso I, Paz-Garcia J, Valtierra-Alvarez J, Preciado-Ramirez J, Almeida-Trinidad R, Guzman-Esquivel J, et al. A phase I-II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee. Eur J Med Res. 2018;23(1):52. DOI: 10.1186/s40001-018-0349-2.